HOFSETH BIOCARE ASA: DISCLOSURES OF LARGE SHAREHOLDINGS

Reference  is made to the stock  exchange announcements from Hofseth BioCare ASA
("HBC"  or the "Company") published on 26 June 2026 and 29 June 2026 regarding a
private  placement  (the  "Private  Placement")  of  new ordinary shares ("Offer
Shares")  at a  fixed price  per share  of NOK  1.30 (the "Offer  Price"), which
raised gross proceeds of approximately NOK 144.5 million.

The  following shareholders of the Company have, on 28 June 2026, been allocated
new  shares  in  the  Private  Placement  which implies that their holdings have
surpassed a notifiable threshold:

  * Hofseth International AS have been allocated 30,384,615 Offer Shares in the
    Private Placement, the subscription of which is subject to approval by an
    extraordinary general meeting of the Company expected to be held on or about
    30 July 2026. The overall size of the Private Placement implies that Hofseth
    International AS's portion of the shares in the Company has increased above
    the 20% threshold, while Hofseth International AS's portion of the votes in
    the Company has not passed a notifiable threshold. Following the Private
    Placement, Hofseth International AS holds 105,996,387 ordinary shares in the
    Company and 16,000,000 unlisted preference shares in Class B without voting
    rights, corresponding to 20.30 % of the shares in the Company and 17.78% of
    the votes at the Company's general meetings.
  * Scatterty Holdings Ltd. have subscribed for 38,416,538 new shares in the
    Private Placement. Following this, Scatterty Holdings Ltd. holds 38,416,538
    shares in the Company, corresponding to 7.36% of the shares in the Company
    and 7.60% of the votes at the Company's general meetings.

The  following shareholders have had their  holdings diluted as a consequence of
the Private Placement and thereby passed a notifiable threshold:

  * Following the Private Placement, RH Industri AS's portion of the shares and
    votes in the Company has fallen below the notifiable 15% threshold. After
    the Private Placement, RH Industri AS continues to hold 69,300,190 shares in
    the Company, which, following the Private Placement, will correspond to
    13.27% of the shares in the Company and 13.69% of the votes at the Company's
    general meetings.
  * Following the Private Placement, Yokorei Co. Ltd.'s portion of the votes in
    the Company has fallen below the notifiable 10% threshold. After the Private
    Placement, Yokorei Co. Ltd. continues to hold 40,951,333 shares in the
    Company, which, following the Private Placement, will correspond to 7.84% of
    the shares in the Company and 8.09% of the votes at the Company's general
    meetings.

Roger  Hofseth is the  controlling shareholder of  both Hofseth International AS
and  RH Industri AS.  After the Private  Placement, Roger Hofseth and associated
parties  holds 175,483,243 shares in the Company (of which 16,000,000 shares are
unlisted  preference shares in Class B  without voting rights), which, following
the  Private Placement, will  correspond to 33.60% of  the shares in the Company
and 31.5% of the votes at the Company's general meetings.

The  issuance of  Offer Shares  to Hofseth  International AS  remains subject to
approval  by an extraordinary general  meeting, expected to be  held on or about
30 July  2026, however the Company has secured sufficient voting undertakings in
order to ensure that this resolution will be passed at the extraordinary general
meeting.

This  disclosure is  made pursuant  to section  4-2 of the  Norwegian Securities
Trading  Act and  is subject  to the  disclosure requirement pursuant to section
5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no (mailto:joo@hofsethbiocare.no)
lav Ødegård\, CEO at HBC\
Phone: +47 936 32 966\
E-mail: joo@hofsethbiocare.no (mailto:joo@hofsethbiocare.no)\